Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. - Wikidata - wikimedia - TriplyDB

Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.

Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.

http://www.wikidata.org/entity/Q54274119

about

Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications.The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions.Clonotypic analysis of immunoglobulin heavy chain sequences in patients with Waldenström's macroglobulinemia: correlation with MYD88 L265P somatic mutation status, clinical features, and outcome MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome.L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations.Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas.Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma.XIII. Waldenström's macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features.Lessons from next-generation sequencing analysis in hematological malignancies.Genetic factors and pathogenesis of Waldenström's macroglobulinemia.MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders.Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models Waldenström macroglobulinemia: from biology to treatment.MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.Identification of the potential risk factors for monoclonal gammopathy of undetermined significance of progression.Disease-specific mutations in mature lymphoid neoplasms: recent advances.Splenic marginal-zone lymphoma: ontogeny and genetics.Ibrutinib for the treatment of Waldenström macroglobulinemia.Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases.Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy.Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.CSF analysis for protein biomarker identification in patients with leptomeningeal metastases from CNS lymphoma.Diagnosis and classification of hematologic malignancies on the basis of genetics.Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.Conformational dynamics of cancer-associated MyD88-TIR domain mutant L252P (L265P) allosterically tilts the landscape toward homo-dimerization.MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma.Lymphoplasmacytic Lymphoma Presenting with Diarrhea and Joint Pain Which was Successfully Diagnosed by an MYD88 Mutation Analysis.Prognostic relevance of protein expression, clinical factors, and MYD88 mutation in primary bone lymphoma.

P2860

Q27027493-7CF27567-9D3B-4553-B735-3D636AE37F54 Q30299913-CA68421C-75D8-4E1B-9E14-03D13F0CE0F2 Q30459093-4580E844-5886-4A85-A254-34370C2F2379 Q33617237-0FECC660-FB7A-4A74-9D31-29430AFD0EE8 Q33660823-4A4E763F-2CAC-4A7A-8D48-C6764E664739 Q33746746-8471FEE3-2204-4BDF-A30B-8020E7B890CE Q33798887-76EBEA6B-0E00-4EEC-8B9B-556BA4500F8F Q34101118-11D17609-A9AD-4F7D-BC90-1A99643CA5F6 Q34435295-6FC8F593-B0E1-40BB-97DB-0E2869930105 Q35041614-0AC202DE-4A65-496E-B7F4-6C792707B6F4 Q36058393-461DC8B9-3188-4F35-9A35-4E04D506C44E Q36203511-8555CD82-DFC7-43C3-BC4C-F660388170FF Q36533710-36B86F82-37F9-46D7-A0E2-6F7EEE574FEA Q37318677-5FE50145-CCEE-4B52-A450-DB36DB98D3BE Q37621361-0DC00CA0-3E4D-4E76-9F57-C1523862E09A Q38115233-31C02B1B-0534-4DF1-8884-72BF1909DD60 Q38123015-40BD6774-DCC2-4EF5-83DC-7AF4CCD11A90 Q38125430-21C335C3-F73A-4617-A980-6DEF053156F3 Q38129753-F045E937-9998-48A3-BF19-424209B55926 Q38150849-03FBE4E7-CE49-48BB-B612-0169F3DC08A2 Q38176969-37B4AAEA-90E9-4F13-9CAF-6C449E9E1A54 Q38191449-D9565168-4DEB-4547-B14E-C8F3C134419F Q38199534-BBBF0878-F94D-4299-8259-DCFEBD3F24DF Q38201143-A41A001F-28E8-48A1-9A6C-BCC889A7EA1A Q38209575-3AF8466D-37C9-4998-9B80-DD2A039C5974 Q38542260-CF17619F-E90E-4F39-88F7-5F517B033485 Q38571471-3C7F685F-30CC-401D-8A2E-49B8925F9E75 Q38747789-B987F888-5BD2-4E14-9F8C-5B3594817539 Q38760522-BD3C9E3E-4867-47CD-8BBF-2ACB55B02F5F Q38839148-9358B91C-8819-49F6-B5AC-70CC9CA799B6 Q38970612-A27F0294-C380-431B-A98C-1981FC85CD71 Q39178864-D7164861-1241-45ED-AC4E-575605DF470E Q39363409-E09FCBDF-8DB7-47BC-9138-B1509D72C2C6 Q39375290-A12E0A90-BE93-4CC6-93C8-6A7D1EC0D980 Q39406673-9258A324-4F90-43AA-AFC7-B5C7A6549B5E Q40954949-FC2F37D0-68B5-477C-A7AC-2F52BCEACD13 Q41374007-DFDAC531-84B8-40C7-8BB3-1E1DEC261507 Q41521972-A56D9FD0-FA86-4B73-819A-40978D0FE6CE Q42223732-7AA3A84D-328A-4862-A882-7F1B50826F3B Q42371562-9A9061D0-B722-4763-8505-ADEAF221200F

P2860

Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.

http://www.wikidata.org/entity/Q54274119

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Prevalence and clinical signif ...... nd related lymphoid neoplasms.

@en

Prevalence and clinical significance of the MYD88

@nl

type

label

Prevalence and clinical signif ...... nd related lymphoid neoplasms.

@en

Prevalence and clinical significance of the MYD88

@nl

prefLabel

Prevalence and clinical signif ...... nd related lymphoid neoplasms.

@en

Prevalence and clinical significance of the MYD88

@nl

P1433

Q54274119-269AD568-92F2-465A-9C92-9B0A8F418832

P1476

Q54274119-6119A15E-2091-4EDC-89A3-3A86AC153820

P2093

Q54274119-041DCC98-982C-423E-8335-F552D7A728E9

Q54274119-0CD80232-A254-4BCE-B037-013959E5ABC4

Q54274119-2EDD5A25-C7CA-49AC-9924-7D7CCB436064

Q54274119-3968E6EA-EB41-4204-B240-4F811D7650CE

Q54274119-4A173AD6-2161-485F-B861-53E7E8530DEB

Q54274119-659DE4B6-3E5B-4DDF-9154-B67B279AB64A

Q54274119-744547C3-2678-44FE-A7DB-42BE2360AFBE

Q54274119-74B24936-85F9-42B4-BD12-D6485E0164F9

Q54274119-9025AD34-F30F-4429-A3F9-4CF405CB6892

Q54274119-96EED2EC-6B18-477F-8FC9-6488DADF0C3E

P304

Q54274119-40F9D424-74F3-41B3-ABDA-3F8BCC10E81B

P31

Q54274119-98DAF8F0-AAC5-42AD-8FEF-45FE17FFF389

P356

Q54274119-A079A96D-5B0F-4BE0-8E66-89772B536029

P407

Q54274119-6D594E70-53AC-48FB-9E6A-7B86949F0DEC

P433

Q54274119-0CD0AA60-39B6-4266-95C6-89B24CA21ED4

P478

Q54274119-093B031E-F2EE-4145-B2BA-4E968928E037

P50

Q54274119-E11759A7-D9BC-491E-B702-C7BA9CD17E80

P577

Q54274119-F494A9D0-34D6-4A45-B982-E03973EC7B12

P5875

Q54274119-C0147940-40CE-4D74-9EB0-71F6D61F8CB8

P698

Q54274119-2C041765-1499-4F87-A84E-DCB08D7F96F7

P356

BLOOD-2012-09-457101

P1433

P1476

Prevalence and clinical signif ...... nd related lymphoid neoplasms.

@en

P2093

Alessandro Corso

http://www.w3.org/2001/XMLSchema#string

Cristiana Pascutto

http://www.w3.org/2001/XMLSchema#string

Emanuela Boveri

http://www.w3.org/2001/XMLSchema#string

Ester Orlandi

http://www.w3.org/2001/XMLSchema#string

Giorgio Croci

http://www.w3.org/2001/XMLSchema#string

Lucia Morello

http://www.w3.org/2001/XMLSchema#string

Manuel Gotti

http://www.w3.org/2001/XMLSchema#string

Marco Paulli

http://www.w3.org/2001/XMLSchema#string

Maria Luisa Guerrera

http://www.w3.org/2001/XMLSchema#string

Mario Cazzola

http://www.w3.org/2001/XMLSchema#string

P304

2522-2528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2012-09-457101

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235377217

http://www.w3.org/2001/XMLSchema#string

P698

23355535

http://www.w3.org/2001/XMLSchema#string